All In Biotech

Drug Trial Radar · NCT02285647

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

Last checked: Nov 20, 2026Latest source record: Aug 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingTitle says "pivotal". Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

138

Actual

Start

Sep 2014

Primary completion

Apr 2015

Study completion May 2015

Sponsor

Lead sponsor
Tesaro, Inc.GSK (GSK)
Sponsor type
Industry
First posted
Nov 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

  • Rolapitant - OralDrug

    Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)

  • Rolapitant - IVDrug

    IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentrationTime frame: 39-69 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.